Giancarlo Benelli brings over two decades of experience in the pharmaceutical industry, rooted in his unique journey from surgery and military service.
BeiGene has claimed a second EU approval for PD-1 inhibitor tislelizumab in non-small cell lung cancer (NSCLC), opening the door to the first launches of the drug outside